- Home
- LOCO vs ALDX Comparison
LOCO vs ALDX Comparison
Compare LOCO & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LOCO
- ALDX
- Stock Information
- Founded
- LOCO 1980
- ALDX 2004
- Country
- LOCO United States
- ALDX United States
- Employees
- LOCO N/A
- ALDX N/A
- Industry
- LOCO Restaurants
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- LOCO Consumer Discretionary
- ALDX Health Care
- Exchange
- LOCO Nasdaq
- ALDX Nasdaq
- Market Cap
- LOCO 327.1M
- ALDX 304.9M
- IPO Year
- LOCO 2014
- ALDX 2014
- Fundamental
- Price
- LOCO $10.28
- ALDX $6.73
- Analyst Decision
- LOCO Buy
- ALDX Strong Buy
- Analyst Count
- LOCO 3
- ALDX 2
- Target Price
- LOCO $15.50
- ALDX $10.00
- AVG Volume (30 Days)
- LOCO 333.3K
- ALDX 666.8K
- Earning Date
- LOCO 03-06-2025
- ALDX 05-01-2025
- Dividend Yield
- LOCO N/A
- ALDX N/A
- EPS Growth
- LOCO 16.22
- ALDX N/A
- EPS
- LOCO 0.86
- ALDX N/A
- Revenue
- LOCO $473,008,000.00
- ALDX N/A
- Revenue This Year
- LOCO $6.09
- ALDX N/A
- Revenue Next Year
- LOCO $1.28
- ALDX N/A
- P/E Ratio
- LOCO $12.09
- ALDX N/A
- Revenue Growth
- LOCO 0.93
- ALDX N/A
- 52 Week Low
- LOCO $8.17
- ALDX $2.75
- 52 Week High
- LOCO $14.25
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- LOCO 39.25
- ALDX 57.30
- Support Level
- LOCO $9.99
- ALDX $6.22
- Resistance Level
- LOCO $10.40
- ALDX $7.20
- Average True Range (ATR)
- LOCO 0.48
- ALDX 0.53
- MACD
- LOCO -0.03
- ALDX -0.01
- Stochastic Oscillator
- LOCO 34.09
- ALDX 79.59
About LOCO El Pollo Loco Holdings Inc.
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.